You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞銀窩輪》中海油得北水青睞  看好參考海油購11047
阿思達克 09-15 17:53
經過週二美股大跌後,週三道指高低波幅400點左右,納指高低波幅約1.2%左右,香港大市則回復窄幅上落,週四港股輕微低開之後抽升至曾重上19000點,之後主要在上下100點左右上落。週三大幅向下的科技股亦普遍回歸平靜,反而週二受到美國制裁所困擾的藥明(2269)股價在連跌兩日後終見明顯反彈,連帶其他醫藥科技相關股份均見反彈,雖然藥明週四反彈6.6%,最高曾重上55港元,不過藥明股價比急跌前約66港元的位置,現仍屬低水平,所以週四仍有資金留意藥明相關好倉,博股價可進一步反彈。事實上,藥明現時的9天和14天的RSI相對強弱指數均已跌穿30,為市場人士普遍認為超賣的水平,如投資者看好藥明,可留意藥明認購11540,行使價60.05港元,23年2月到期,有效槓桿約3.6倍。 近日能逆市造好的要數中海油(0883),公司連續兩日回購股份,兩日累計回購超過1700萬股,而且中海油亦成為北水愛股,單是週三已有6.59億港元北水透過滬港通淨流入中海油。技術上中海油已突破50天和100天線,近3個月在9.5港元以及11港元之間上落,投資者可留意股價能否借回購的勢頭再次挑戰11港元水平。如投資者看好海油,可留意海油認購11047,行使價11.193港元,23年1月到期,有效槓桿約7.6倍。 再留意美股,週三雖然收市升跌幅不大,但道指、納指兩指數在週三收市前均曾見當日低位並隨即得到買盤支持,呈強勁反彈。納指半小時內抽升1%,道指在相約時間由低位抽急升約250點,或反映指數在但位得到資金支持,且留意週四晚美股的表現。不過週買港股時段不少資金已買入相關的認股證先行部署。如投資者看好納指,可留意納指認購10427,行使價13500點,22年12月到期,有效槓桿約12.倍;相反,如投資者看淡納指,可留意納指認沽10528,行使價10750點,22年12月到期,有效槓桿約9.1倍。如投資者看好道指,可留意道指認購10620,行使價35000點,23年3月到期,有效槓桿約10倍;相反,如投資者看淡道指,可留意道指認沽10509,行使價26400點,22年12月到期,有效槓桿約12倍。 更多窩輪牛熊資訊:瑞銀認股證牛熊證網站: http://www.ubs.com/hkwarrants 輪證教學及巿況焦點短片: https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber 卓素華 瑞銀亞洲上市衍生產品銷售部主管 本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2022。版權所有。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account